Competition is good. Early stage drugs confirm the market size. If it costs $300m to take the drug through trials, along with all the risks, the market must be big enough to warrent the investment. Luckily for us biota is the leader and with an approved next generation drug in Japan. Even more lucky to have approved non dilutive funding for all the trials. Biota is well undervalued. I just wish I had a spare bar to throw into it!
